Osivax and GC Biopharma revealed a new alliance aimed at developing a next-generation influenza vaccine. The vaccine will combine OVX836 and GC FLU. Osivax secured the rights for pursuing a combination shot.
Older adults must weigh four vaccine decisions this fall, while the federal immunization calendar continues to carry a 2025 date. Flu and pneumonia deaths have fallen for 25 years, but one American age group saw an increase.